Epigallocatechin-3-gallate(EGCG) Suppresses Melanoma Cell Growth and Metastasis by Targeting TRAF6 Activity

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Oct 30

PMID 27791197

Citations 46

Authors

Jianglin Zhang

Zhou Lei

Zunnan Huang

Xu Zhang

Youyou Zhou

Zhongling Luo

Weiqi Zeng

Juan Su

Cong Peng

Xiang Chen

Affiliations

Soon will be listed here.

Abstract

TRAF6 (TNF Receptor-Associated Factor 6) is an E3 ubiquitin ligase that contains a Ring domain, induces K63-linked polyubiquitination, and plays a critical role in signaling transduction. Our previous results demonstrated that TRAF6 is overexpressed in melanoma and that TRAF6 knockdown dramatically attenuates tumor cell growth and metastasis. In this study, we found that EGCG can directly bind to TRAF6, and a computational model of the interaction between EGCG and TRAF6 revealed that EGCG probably interacts with TRAF6 at the residues of Gln54, Gly55, Asp57 ILe72, Cys73 and Lys96. Among these amino acids, mutation of Gln54, Asp57, ILe72 in TRAF6 could destroy EGCG bound to TRAF6, furthermore, our results demonstrated that EGCG significantly attenuates interaction between TRAF6 and UBC13(E2) and suppresses TRAF6 E3 ubiquitin ligase activity in vivo and in vitro. Additionally, the phosphorylation of IκBα, p-TAK1 expression are decreased and the nuclear translocation of p65 and p50 is blocked by treatment with EGCG, leading to inactivation of the NF-κB pathway. Moreover, EGCG significantly inhibits cell growth as well as the migration and invasion of melanoma cells. Taken together, these findings show that EGCG is a novel E3 ubiquitin ligase inhibitor that could be used to target TRAF6 for chemotherapy or the prevention of melanoma.

Citing Articles

Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities.

Awan A, Osman M, Khan O Cells. 2025; 14(2).

PMID: 39851497 PMC: 11763706. DOI: 10.3390/cells14020069.

Green Tea Catechins and Skin Health.

Zheng X, Zhang X, Gao H, Huang L, Ye J, Ye J Antioxidants (Basel). 2025; 13(12.

PMID: 39765834 PMC: 11673495. DOI: 10.3390/antiox13121506.

A recent update on the connection between dietary phytochemicals and skin cancer: emerging understanding of the molecular mechanism.

Singh H, Mishra A, Mohanto S, Kumar A, Mishra A, Amin R Ann Med Surg (Lond). 2024; 86(10):5877-5913.

PMID: 39359831 PMC: 11444613. DOI: 10.1097/MS9.0000000000002392.

Polyphenols alleviate metabolic disorders: the role of ubiquitin-proteasome system.

Gu W, Wu G, Chen G, Meng X, Xie Z, Cai S Front Nutr. 2024; 11:1445080.

PMID: 39188976 PMC: 11345163. DOI: 10.3389/fnut.2024.1445080.

Exploring the Role of Ubiquitin-Proteasome System in the Pathogenesis of Parkinson's Disease.

Zhao Y, Lin M, Zhai F, Chen J, Jin X Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931449 PMC: 11207014. DOI: 10.3390/ph17060782.

References

Widlansky M, Hamburg N, Anter E, Holbrook M, Kahn D, Elliott J . Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr. 2007; 26(2):95-102. PMC: 3773609. DOI: 10.1080/07315724.2007.10719590. View

Gillespie K, Kodani I, Dickinson D, Ogbureke K, Camba A, Wu M . Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren's syndrome, an autoimmune disease. Life Sci. 2008; 83(17-18):581-8. PMC: 2701648. DOI: 10.1016/j.lfs.2008.08.011. View

Tang R, Xu X, Yang W, Yu W, Hou S, Xuan Y . MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways. Cancer Lett. 2016; 373(1):77-87. DOI: 10.1016/j.canlet.2016.01.005. View

Friesner R, Murphy R, Repasky M, Frye L, Greenwood J, Halgren T . Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006; 49(21):6177-96. DOI: 10.1021/jm051256o. View

Friesner R, Banks J, Murphy R, Halgren T, Klicic J, Mainz D . Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004; 47(7):1739-49. DOI: 10.1021/jm0306430. View

Freeman-Keller M, Weber J . Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol. 2015; 7(1):12-21. PMC: 4265090. DOI: 10.1177/1758834014551747. View

Yin Q, Lin S, Lamothe B, Lu M, Lo Y, Hura G . E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol. 2009; 16(6):658-66. PMC: 2834951. DOI: 10.1038/nsmb.1605. View

Lamothe B, Besse A, Campos A, Webster W, Wu H, Darnay B . Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem. 2006; 282(6):4102-12. PMC: 3221607. DOI: 10.1074/jbc.M609503200. View

Wu L, Grigoryan A, Li Y, Hao B, Pagano M, Cardozo T . Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol. 2012; 19(12):1515-24. PMC: 3530153. DOI: 10.1016/j.chembiol.2012.09.015. View

10.

Chen D, Pamu S, Cui Q, Chan T, Dou Q . Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg Med Chem. 2012; 20(9):3031-7. PMC: 3334407. DOI: 10.1016/j.bmc.2012.03.002. View

11.

Afaq F, Adhami V, Ahmad N, Mukhtar H . Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate. Oncogene. 2003; 22(7):1035-44. DOI: 10.1038/sj.onc.1206206. View

12.

Starczynowski D, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A . Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2009; 16(1):49-58. DOI: 10.1038/nm.2054. View

13.

Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J . Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. Oncotarget. 2015; 6(13):10746-58. PMC: 4484416. DOI: 10.18632/oncotarget.3628. View

14.

Weissman A, Shabek N, Ciechanover A . The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell Biol. 2011; 12(9):605-20. PMC: 3545438. DOI: 10.1038/nrm3173. View

15.

Mattern M, Wu J, Nicholson B . Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors. Biochim Biophys Acta. 2012; 1823(11):2014-21. PMC: 7127515. DOI: 10.1016/j.bbamcr.2012.05.005. View

16.

Ranzani M, Alifrangis C, Perna D, Dutton-Regester K, Pritchard A, Wong K . BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell Melanoma Res. 2014; 28(1):117-9. PMC: 4296225. DOI: 10.1111/pcmr.12316. View

17.

Kishida S, Sanjo H, Akira S, Matsumoto K, Ninomiya-Tsuji J . TAK1-binding protein 2 facilitates ubiquitination of TRAF6 and assembly of TRAF6 with IKK in the IL-1 signaling pathway. Genes Cells. 2005; 10(5):447-54. PMC: 1224749. DOI: 10.1111/j.1365-2443.2005.00852.x. View

18.

Pfeifer G, Besaratinia A . UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer. Photochem Photobiol Sci. 2011; 11(1):90-7. PMC: 3289542. DOI: 10.1039/c1pp05144j. View

19.

Enzler T, Sano Y, Choo M, Cottam H, Karin M, Tsao H . Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov. 2012; 1(6):496-507. PMC: 3290412. DOI: 10.1158/2159-8290.CD-11-0143. View

20.

Watanabe M, Umezawa K, Higashihara M, Horie R . Combined inhibition of NF-κB and Bcl-2 triggers synergistic reduction of viability and induces apoptosis in melanoma cells. Oncol Res. 2014; 21(4):173-80. DOI: 10.3727/096504014X13887748696707. View